Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MFSF
1551
DELISTED
MutualFirst Financial Inc
MFSF
| $6.36M | 0.01% |
178,100
+11,619
| +7% | +$391K |
|
1552
GSI Technology
GSIT
$270M
| $6.36M | 0.01% |
808,700
+53,700
| +7% | +$428K |
|
1553
Ryman Hospitality Properties
RHP
$7.91B
| $6.35M | 0.01% |
99,241
+23,100
| +30% | +$1.47M |
|
1554
WEX
WEX
$6.55B
| $6.34M | 0.01% |
60,800
-78,700
| -56% | -$8.1M |
|
1555
Paycom
PAYC
$9.84B
| $6.34M | 0.01% |
92,650
-59,600
| -39% | -$3.83M |
|
1556
Flowers Foods
FLO
$1.59B
| $6.33M | 0.01% |
+365,938
| New | +$6.88M |
|
|
HMTV
1557
DELISTED
Hemisphere Media Group, Inc.
HMTV
| $6.33M | 0.01% |
534,244
+74,796
| +16% | +$862K |
|
1558
Interactive Brokers
IBKR
$41.8B
| $6.33M | 0.01% |
676,400
-123,200
| -15% | -$1.09M |
|
|
FMBI
1559
DELISTED
First Midwest Bancorp Inc/IL
FMBI
| $6.33M | 0.01% |
271,471
-286,700
| -51% | -$6.58M |
|
|
ARAV
1560
DELISTED
Aravive, Inc. Common Stock
ARAV
| $6.33M | 0.01% |
60,418
+24,635
| +69% | +$2.65M |
|
1561
Dawson Geophysical
DWSN
$98.4M
| $6.32M | 0.01% |
1,692,980
+152,166
| +10% | +$666K |
|
1562
Lexicon Pharmaceuticals
LXRX
$1.04B
| $6.32M | 0.01% |
384,097
+122,592
| +47% | +$1.9M |
|
|
FCH
1563
DELISTED
Felcor Lodging Trust
FCH
| $6.31M | 0.01% |
875,002
-431,998
| -33% | -$3.2M |
|
1564
City Holding Co
CHCO
$2.07B
| $6.28M | 0.01% |
95,400
+8,500
| +10% | +$563K |
|
1565
NACCO Industries
NC
$322M
| $6.27M | 0.01% |
387,365
+63,458
| +20% | +$1.06M |
|
|
NSTG
1566
DELISTED
NanoString Technologies, Inc.
NSTG
| $6.26M | 0.01% |
378,300
+28,300
| +8% | +$500K |
|
1567
Petrobras Class A
PBR.A
$103B
| $6.22M | 0.01% |
833,400
-625,800
| -43% | -$5.3M |
|
1568
Crawford & Co Class B
CRD.B
$593M
| $6.21M | 0.01% |
667,303
+4,403
| +0.7% | +$42.8K |
|
1569
Zumiez
ZUMZ
$315M
| $6.2M | 0.01% |
+502,273
| New | +$7.67M |
|
1570
Visa
V
$682B
| $6.19M | 0.01% |
66,000
+14,200
| +27% | +$1.32M |
|
|
SRGA
1571
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $6.18M | 0.01% |
35,239
+9,942
| +39% | +$1.41M |
|
1572
Rocky Mountain Chocolate Factory
RMCF
$11.4M
| $6.18M | 0.01% |
525,485
+17,415
| +3% | +$207K |
|
1573
Innospec
IOSP
$2.31B
| $6.16M | 0.01% |
94,000
-154,100
| -62% | -$9.9M |
|
1574
Eastern Company
EML
$151M
| $6.15M | 0.01% |
204,800
+9,627
| +5% | +$271K |
|
1575
Prosperity Bancshares
PB
$9.03B
| $6.13M | 0.01% |
+95,388
| New | +$6.29M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.